Publications

Lord CJ, Tutt ANJ, Ashworth A. Two decades of PARP inhibitor synthetic lethality in cancer. Nature. 2026. PMID: 42092061

Rajeeve S, Wilkes M, Zahradka N, Tomalin L, Quidwai M, Pan D, Calafat NJ, Cusack M, Aleman A, Serebryakova K, Kappes K, Jackson H, Agte S, Thibaud S, Sanchez L, Richard S, Richter J, Rodriguez C, Cho HJ, Chari A, Jagannath S, Laganà A, Rossi AC, Parekh S. Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma. JCI insight. 2026. PMID: 42084945

Bahlis NJ, Facon T, San-Miguel JF, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje NS, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel KC, Mohty M, Leleu X, Plesner T, Jakubowiak AJ, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK. Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE. Blood advances. 2026. PMID: 42085642

Lacouture ME, Pan A, Maier T, Chen A, Dranitsaris G, Shah NJ, Dang C, Gajria D, Gordon A, Iyengar N, Razavi P, Robson M, Rosen E, Wong S, Harris U, Ketosugbo K, Bravo C, Jain M, Markova A. Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 42084605

Stauffer C, Brantly NW, Beam DW, Bose R, Fiedler G, Fisher LE. 3D printing and prostheses: The current state-of-the-art and future directions. Journal of rehabilitation and assistive technologies engineering. 2026. PMID: 42124558

Orgeta V, Kidd G, Stafford J, Leung P, Marston L, Sidebottom A, Fong L. Characteristics of missing incidents and risk factors for harm for older people with and without dementia in the UK. Age and ageing. 2026. PMID: 42120014

Odintsov I, Tazelaar HD, Lee JC, Damon LE, Devine WP, Jones KD. Novel BRAF fusion in Erdheim-Chester disease with pulmonary manifestations: Importance of RNA-based testing and response to MEK inhibition. Histopathology. 2026. PMID: 42082348

Chow R, Zhang D, Kannout S, Ma A, Zheng C, Blayne A, Dou A, Talwar S, Fazelzad R, Rugo HS, Ruhlmann CH, Iihara H, Affronti ML, Leigh J, Scotté F, Eng L, MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group. Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026. PMID: 42068413

Khozin S, Dreyer NA, Galante D, Liu R, Neumann P, Nussbaum N, O'Shaughnessy J, Rimawi MF, Rugo HS, Tolaney SM, Weiss M, Brufsky A. Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative. Advances in therapy. 2026. PMID: 41843049

Venook AP. How to implement DPYD genotyping into practice. Clinical advances in hematology & oncology : H&O. 2026. PMID: 42096684

Widder J, Bol GM, Simek IM, Ehret F, Abdel-Aty H, Basic S, Chuter D, Daly J, Fairbrother P, Zeqa D, Aboubakar Nana F, Achard V, Corradini S, Correia D, De Ruysscher D, Dingemans AC, Faivre-Finn C, Gillessen S, Guren MG, Hendriks L, Kunz WG, Lecouvet FE, Levy A, Lievens Y, McDonald F, Meattini I, Oppong F, Oprea-Lager D, Palma D, Fredberg Persson G, Remon J, Vandemaele M, van Laarhoven HWM, Verkooijen HM, Visani L, Zilli T, Ost P, Guckenberger M. Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium. The Lancet. Oncology. 2026. PMID: 42061381

Shah NJ, Ababio Y, Eccleston A, Rao D, Kelly SP, Chang J, Lucht S, Paydar C, Van Doren BA, Bland E, John W, Giegerich S, Laney J, Feinberg B, Zarrabi KK. Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma. JAMA network open. 2026. PMID: 42166160

Wang T, Ferreira AC, Hossain NM, Fu D, Hill EG, Jimenez Jimenez AM, Benjamin C, Komanduri KV, Paczesny S. Day-30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation. British journal of haematology. 2026. PMID: 42047487

Li C, Ke F, Zhao H, Mao S, Djibo M, Huang L, He M, Wang M, Wen H, Liu Z, Yu Z, Qi Z, Xavier AR, Nenwani M, Wen B, Peterson N, Sahai V, Nagrath D, Lucas CL, Wymann MP, Gao W, Fong L, Sun D. Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer. Nature cancer. 2026. PMID: 42049931

Chen DD, Zimmer A, Yang DD, Francini E, Patton R, Crowdis J, Chandra P, Bin Riaz I, Hanratty B, Rickles-Young M, Tsuji J, Cibulskis C, Fleharty M, Whelpley B, Reardon B, Park J, Nelson PS, Huang FW, Van Allen EM, Ha G, Choudhury AD. Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer. NPJ precision oncology. 2026. PMID: 42049996

Kennedy VE, Peretz CAC, Koh A, Tran E, Dhingra D, Gulati S, Sciambi A, Sala-Torra O, Beppu L, Radich JP, Smith CC. Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML. European journal of haematology. 2026. PMID: 42046307

Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat Y, Stein E, Deininger MW, Schiller G, Pollyea DA, Foran JM, Olin R, Lin T, Boyiadzis MM, Handa S, Rueter B, Gana TJ, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus S, Rosenberg L, Druker B, Levine R, Burd A, Yocum AO, Byrd JC, Blum W. Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results. Haematologica. 2026. PMID: 42021690

Lancman G, Sastow D, Aslanova M, Moshier E, Cho HJ, Jagannath S, Parekh S, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez L, Thibaud S, Chari A. Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab. Haematologica. 2026. PMID: 42021698

Talbot A, Li K, Lee JHJ, Lang S, Liu C, Kalter N, Li Z, Mortazavi Y, Almudhfar N, Muldoon JJ, Allain V, Nyberg W, Chung JJ, Wang C, Qi Z, Krishnappa N, Ha AS, Kong D, Houser D, Paruthiyil S, Ahmadi M, Ji Y, Rosenberg M, Acevedo LA, Liang B, Briseno K, Kwek SS, Giannikopoulos P, Rivière I, Sadelain M, Oh DY, Marson A, Hendel A, Martin T, Eyquem J, Shy BR. Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma. bioRxiv : the preprint server for biology. 2026. PMID: 42079140

Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, Bonnefoi H, Kim SB, Hirmas N, Bear H, Witkiewicz AK, Im SA, DeMichele A, Veer LV, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff C, Kelly CM, Reimer T, Olivé MM, Knudsen ES, van Mackelenbergh M, Rojo F, Frickel N, Fasching PA, Teply-Szymanski J, Toi M, Rugo HS, Gnant M, Makris A, Felder B, Nekljudova V, Loibl S. Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2026. PMID: 42025846